Medical Properties Trust, Inc. (MPT)
NYSE: MPT · Real-Time Price · USD
4.830
+0.080 (1.68%)
At close: Apr 9, 2026, 4:00 PM EDT
4.880
+0.050 (1.04%)
After-hours: Apr 9, 2026, 4:15 PM EDT
Medical Properties Trust Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Medical Properties Trust stock has a target of 5.00, which predicts a 3.52% increase from the current stock price of 4.83.
Price Target: $5.00 (+3.52%)
Analyst Consensus: Hold
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Medical Properties Trust is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $4.5 → $5 | Hold | Maintains | $4.5 → $5 | +3.52% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
1.01B
from 1.07B
Decreased by -5.60%
Revenue Next Year
1.06B
from 1.01B
Increased by 4.75%
EPS This Year
0.09
from -0.46
EPS Next Year
0.16
from 0.09
Increased by 71.20%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.1B | 1.2B | |||
| Avg | 1.0B | 1.1B | |||
| Low | 925.8M | 917.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.3% | 15.7% | |||
| Avg | -5.6% | 4.8% | |||
| Low | -13.5% | -9.2% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 0.15 | 0.23 |
| Avg | 0.09 | 0.16 |
| Low | 0.05 | 0.12 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | 148.6% |
| Avg | - | 71.2% |
| Low | - | 26.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.